Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia

Background: Schizophrenia is a chronic debilitating disease. The pathogenesis and treatment may be associated with inflammatory cytokines. There are few studies focusing on the prediction of cytokines in response to antipsychotics. Aim: To investigate whether cytokines would predict response to antipsychotics. Methods: Cross-sectional and natural observational cohort studies were applied to:(1) compare the baseline levels of serum IL-1β, TNF-α and MCP-1 between schizophrenia (n=64) and healthy controls (n=53); (2) To investigate the impact of baseline cytokines to psychopathology following olanzapine and risperidone monotherapy. 结果: （1）精神分裂症患者治疗前血清MCP-1 水平 明显高于健康对照组（t=2.62, p=0.010），IL-1β（t=1.43 p=0.154）、TNF-α（t=0.79, p=0.434）未见变化；（2） 精神分裂症患者治疗前MCP-1 水平与利培酮单药治疗 4 周后PANSS 量表一般病理评分的减少量呈显著负相 关（r =-0.658; p ﹤ 0.001），但在奥氮平组中则未发现（r =-0.031; p=0.855）；（3）纳入性别、年龄、受教育年 限和BMI 后等影响因素后，多元线性回归分析发现， 基线血清MCP-1 水平可作为利培酮单药治疗效果的独 立预测因子（校正R2= 0.409, β= -0.658, p ﹤ 0.001）。. 结论: MCP-1 可能参与精神分裂症的发生，治疗前血 清MCP-1 水平可能是利培酮疗效预测的生物标记物。.